New therapeutic targets in soft tissue sarcoma

Advances in Anatomic Pathology

Volumn 19, Issue 3, 2012, Pages 170-180

  Demicco, Elizabeth G ^a   Maki, Robert G ^b   Lev, Dina C ^a   Lazar, Alexander J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

molecular mechanisms; soft tissue sarcoma; targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; AZD 8055; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CEDIRANIB; CRIZOTINIB; DEFEROLIMUS; DULAMNERMIN; FIGITUMUMAB; GANETESPIB; GSK 1059615; IMATINIB; ISPINESIB; MK 2206; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; OBLIMERSEN; PANOBINOSTAT; PAZOPANIB; R 1507; RAPAMYCIN; RETASPIMYCIN; RG 7112; SELUMETINIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; EWING SARCOMA; FUSION GENE; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; KARYOTYPE; MITOSIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TRANSCRIPTION REGULATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; SARCOMA; SOFT TISSUE NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860007065     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318253462f     Document Type: Review

References (160)

1. Fletcher CDM, Rydholm A, Singer S, et al. Soft tissue tumours: epidemiology, clinical features, histopathological typing and grading. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:9-18.
2. Steen S, Stephenson G. Current treatment of soft tissue sarcoma. Proc (Bayl Univ Med Cent). 2008;21:392-396.
3. Demetri GD, Antonia S, Benjamin RS, et al. Soft tissue sarcoma. J Natl Compr Canc Netw. 2010;8:630-674.
4. Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701-711. (Pubitemid 41175678)
5. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
6. Orphan Drug Act. US Pub. L No 97-414. 1983.
7. Haffner ME. Adopting orphan drugs-two dozen years of treating rare diseases. N Engl J Med. 2006;354:445-447. (Pubitemid 43200295)
8. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther. 2007;6: 1175-1179. (Pubitemid 46711980)
9. Demicco EG, Lazar AJ. Clinicopathologic considerations: how can we fine tune our approach to sarcoma. Semin Oncol. 2011;38:S3-S18.
10. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294.
11. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res. 2000;462:247-253. (Pubitemid 30190232)
12. Fisher C. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations. Virchows Arch. 2010;456:153-166.
13. Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010;456:219-234.
14. Berner JM, Forus A, Elkahloun A, et al. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer. 1996;17:254-259. (Pubitemid 26424003)
15. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011;50:25-33.
16. Hachitanda Y, Toyoshima S, Akazawa K, et al. N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol. 1998;11:1222-1227. (Pubitemid 29009333)
17. Ueda T, Healey JH, Huvos AG, et al. Amplification of the MYC gene in osteosarcoma secondary to Paget's disease of bone. Sarcoma. 1997;1:131-134. (Pubitemid 28267180)
18. Barrios C, Castresana JS, Ruiz J, et al. Amplification of the cmyc proto-oncogene in soft tissue sarcomas. Oncology. 1994;51:13-17. (Pubitemid 24008633)
19. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene. 2010;29:1249-1259.
20. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004-3016. (Pubitemid 29276540)
21. Wang J, Hisaoka M, Shimajiri S, et al. Detection of COL1A1- PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription- polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol. 1999;8:113-119. (Pubitemid 29521901)
22. Rutkowski P, Debiec-Rychter M, Nowecki Z, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol. 2011;25:264-270.
23. Cook JR, Dehner LP, CollinsMH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25:1364-1371. (Pubitemid 33022051)
24. Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14: 569-576. (Pubitemid 32554081)
25. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59:2776-2780. (Pubitemid 29283106)
26. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727-1733.
27. Dal Cin P, Sciot R, Samson I, et al. Cytogenetic characterization of tenosynovial giant cell tumors (nodular tenosynovitis). Cancer Res. 1994;54:3986-3987. (Pubitemid 24258097)
28. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006;103:690-695. (Pubitemid 43153087)
29. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23:361-366.
30. Kuroda M, Ishida T, Takanashi M, et al. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol. 1997;151:735-744. (Pubitemid 27385605)
31. Bento C, Andersson MK, Aman P. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2. BMC Cell Biol. 2009;10:89.
32. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8:449-457.
33. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a singleinstitution series. Ann Oncol. 2009;20:1439-1444.
34. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272:30822-30827. (Pubitemid 27527522)
35. El-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990;1:325-331.
36. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest. 1990;86:1806-1814.
37. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24: 7275-7283. (Pubitemid 39014452)
38. Zwerner JP, May WA. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene. 2001;20:626-633. (Pubitemid 32156187)
39. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res. 2001;11:289-297. (Pubitemid 34257726)
40. Ginsberg JP, Davis RJ, Bennicelli JL, et al. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 1998;58:3542-3546. (Pubitemid 28376547)
41. Mercado GE, Xia SJ, Zhang C, et al. Identification of PAX3- FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer. 2008;47:510-520. (Pubitemid 351657186)
42. Lazar AJ, Lahat G, Myers SE, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. Histopathology. 2009;55:750-755.
43. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919-929.
44. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010;70:639-645.
45. Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16:2458-2465.
46. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27:5800-5807.
47. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF- 1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010;11:129-135.
48. Nagayama S, Katagiri T, Tsunoda T, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002;62:5859-5866. (Pubitemid 35204746)
49. Ishibe T, Nakayama T, Okamoto T, et al. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005;11: 2702-2712. (Pubitemid 40569472)
50. Kazanowska B, Reich A, Stegmaier S, et al. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal Pediatr Pathol. 2007; 26:17-31. (Pubitemid 47035965)
51. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679. (Pubitemid 34575640)
52. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998;16: 1248-1255. (Pubitemid 28175736)
53. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol. 1996;14:1245-1251. (Pubitemid 26105532)
54. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010;28:1989-1994.
55. Panagopoulos I, Mertens F, Isaksson M, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer. 2001;31:362-372. (Pubitemid 32622713)
56. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYTSSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-140. (Pubitemid 34073997)
57. Stegmaier S, Poremba C, Schaefer KL, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer. 2011;57:406-414.
58. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21: 4342-4349. (Pubitemid 46621810)
59. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710. (Pubitemid 36159485)
60. Wang CM, Huang K, Zhou Y, et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol. 2010;136: 1065-1071.
61. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338. (Pubitemid 44528723)
62. Cassier PA, Labidi-Galy SI, Heudel P, et al. Therapeutic pipeline for soft-tissue sarcoma. Expert Opin Pharmacother. 2011;12:2479-2491.
63. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456:201-217.
64. Murnane JP. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 2010;70:4255-4259.
65. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144:27-40.
66. Matsuo T, Shimose S, Kubo T, et al. Telomeres and telomerase in sarcomas. Anticancer Res. 2009;29:3833-3836.
67. Venturini L, Motta R, Gronchi A, et al. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer. 2010;10:254.
68. Lafferty-Whyte K, Cairney CJ, Will MB, et al. A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene. 2009;28:3765-3774.
69. Sasaki T, Tazawa H, Hasei J, et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res. 2011;17:1828-1838.
70. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
71. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
72. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51. (Pubitemid 43054973)
73. Lopez G, Torres K, Lev D. Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: potential implications for the treatment of a therapeutic-resistant malignancy. Autophagy. 2011;7:440-441.
74. Lopez G, Torres K, Liu J, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011;71:185-196.
75. Sakimura R, Tanaka K, Nakatani F, et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer. 2005;116:784-792. (Pubitemid 41099711)
76. Ito T, Ouchida M, Morimoto Y, et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett. 2005;224: 311-319. (Pubitemid 40725851)
77. Sampson ER, Amin V, Schwarz EM, et al. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. J Orthop Res. 2011;29: 623-632.
78. Muhlenberg T, Zhang Y, Wagner AJ, et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009;69:6941-6950.
79. Hrzenjak A, Moinfar F, Kremser ML, et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010;9:49.
80. Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discovery. 2011;1:587-597.
81. Kawaguchi K, Oda Y, Saito T, et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol. 2006;19:106-114. (Pubitemid 43250985)
82. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res. 2006;12:6869-6875. (Pubitemid 44974478)
83. Wakahara K, Ohno T, Kimura M, et al. EWS-Fli1 upregulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res. 2008;6:1937-1945.
84. Winter GE, Rix U, Lissat A, et al. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol Cancer Ther. 2011;10:1846-1856.
85. Carol H, Boehm I, Reynolds CP, et al. Efficacy and pharmacokinetic/ pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 2011;68: 1291-1304.
86. Yu Y, Feng YM. The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer. 2010;116: 5150-5160.
87. Carol H, Lock R, Houghton PJ, et al. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009;53:1255-1263.
88. Souid AK, Dubowy RL, Ingle AM, et al. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010;55:1323-1328.
89. Guillou L, Hogendoorn PC, Bosman FT. Soft tissue sarcomas: introduction to the Virchows Archiv review issue. Virchows Arch. 2010;456:107-109.
90. Mejia-Guerrero S, Quejada M, Gokgoz N, et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer. 2010;49:518-525.
91. Mahalingam D, Mita A, Sankhala K, et al. Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets. 2009;10:937-949.
92. Wunder JS, Eppert K, Burrow SR, et al. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene. 1999;18:783-788. (Pubitemid 29080336)
93. Kasper B, Gil T, Awada A. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol. 2007;19:336-340. (Pubitemid 46883522)
94. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308. (Pubitemid 28406815)
95. Wang Y, Mandal D, Wang S, et al. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer. 2010;116:3892-3902.
96. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I doseescalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28:2839-2846.
97. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005; 12(suppl 2):1509-1518. (Pubitemid 41553987)
98. Gupta A, Roy S, Lazar AJ, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA. 2010;107:14333-14338.
99. Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006;5:2592-2601. (Pubitemid 44785803)
100. Bauer S, Yu LK, Demetri GD, et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66:9153-9161. (Pubitemid 44521135)
101. Montemurro M, Bauer S. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. Curr Opin Oncol. 2011;23:367-372.
102. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22:351-355.
103. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-166.
104. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42:715-721.
105. Demicco EG, Torres KE, Ghadimi MP, et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012;25:212-221.
106. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer. 2005;103:1881-1890. (Pubitemid 40563261)
107. Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist. 2008;13:467-473. (Pubitemid 351679928)
108. Cascio MJ, O'Donnell RJ, Horvai AE. Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare. Mod Pathol. 2010;23:574-580.
109. Xie X, Ghadimi MP, Young ED, et al. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011;17:5901-5912.
110. Rikhof B, de Jong S, Suurmeijer AJ, et al. The insulin-like growth factor system and sarcomas. J Pathol. 2009;217: 469-482.
111. Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011;23:352-360.
112. Torres KE, Zhu QS, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17:3943-3955.
113. Goldberg J, Demetri GD, Choy E, et al. Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol. 2009;27(suppl):abstract 10502.
114. Zou CY, Smith KD, Zhu QS, et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009;8:1157-1168.
115. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1Rdependent mechanism. Oncogene. 2007;26:1932-1940. (Pubitemid 46474636)
116. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30:78-84.
117. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28:835-840.
118. Lahat G, Zhang P, Zhu QS, et al. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/ malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology. 2011;59:556-561.
119. Sasaki K, Hitora T, Nakamura O, et al. The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res. 2011;31:549-553.
120. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008; 47:853-859.
121. Lu X, Tang X, Guo W, et al. Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010; 102:821-826.
122. Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther. 2008;7:890-896. (Pubitemid 351551042)
123. Peng CL, Guo W, Ji T, et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther. 2009;8:1729-1736.
124. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082-4090.
125. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-3140.
126. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008;68:5-8. (Pubitemid 351380097)
127. Marampon F, Bossi G, Ciccarelli C, et al.MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther. 2009;8:543-551.
128. Potti A, Ganti AK, Tendulkar K, et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004;130:52-56. (Pubitemid 38161248)
129. West CC, Brown NJ, Mangham DC, et al. Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol. 2005;31:1198-1205. (Pubitemid 41819208)
130. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23:7135-7142.
131. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008;26:5583-5588.
132. Mentzel T, Brown LF, Dvorak HF, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch. 2001;438:13-22. (Pubitemid 32128185)
133. Roma J, Masia A, Reventos J, et al. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res. 2011;17: 505-513.
134. Zhang P, Yang Y, Zweidler-McKay PA, et al. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008;14:2962-2969.
135. Raimondi L, Ciarapica R, De Salvo M, et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ. 2011 [Epub ahead of print].
136. Belyea BC, Naini S, Bentley RC, et al. Inhibition of the notch-hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin Cancer Res. 2011;17:7324-7336.
137. Bennani-Baiti IM, Aryee DN, Ban J, et al. Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma. J Pathol. 2011;225:353-363.
138. Tostar U, Malm CJ, Meis-Kindblom JM, et al. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol. 2006;208: 17-25. (Pubitemid 43025700)
139. Pressey JG, Anderson JR, Crossman DK, et al. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011;57:930-938.
140. Tostar U, Toftgard R, Zaphiropoulos PG, et al. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes Cancer. 2010;1:941-951.
141. Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial. Invest New Drugs. 2011;29:481-488.
142. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29:4541-4547.
143. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2010;17:871-879.
144. Schuetze S, Zhao L, Chugh R, et al. Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma. J Clin Oncol. 2011;29(suppl):abstract 10003.
145. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer. 2011;117:3468-3475.
146. Houghton PJ, Gorlick R, Kolb EA, et al. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011;58:191-199.
147. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627-644.
148. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010;16:530-540.
149. Gorlick R, Maris JM, Houghton PJ, et al. Testing of the Akt/ PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011 [Epub ahead of print].
150. MEK inhibitor AZD6244 with or without temsirolimus in treating patients with metastatic, recurrent, or locally advanced soft tissue sarcoma that cannot be removed by surgery. March 5, 2011. Available at: http://clinicaltrials.gov/ ct2/show/NCT01206140. Accessed January 21, 2012.
151. Yoon SS, Duda DG, Karl DL, et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011;81:1081-1090.
152. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126-3132.
153. Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010;28:5174-5181.
154. Schwartz GK, Maki RG, Ratain MJ, et al. Brivanib (BMS- 582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol. 2011;29(suppl):abstract 10000.
155. Ray-Coquard IL, Blay J, Italiano A, et al. Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): a pharmacodynamic (PD) biomarker study. J Clin Oncol. 2011;29(suppl): abstract 10007b.
156. Rheingold SR, Hogarty MD, Blaney SM, et al. Phase I trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007;25:1512-1518. (Pubitemid 46733077)
157. PD0332991 in patients with advanced or metastatic liposarcoma. October 25, 2011. Available at: http://clinicaltrials. gov/ct2/show/NCT01209598. Accessed January 21, 2012.
158. Efficacy and safety assessment of oral LBH589 in adult patients with advanced soft tissue sarcoma after pre-treatment failure (ESTIM-LBH). July 12, 2011. Available at: http:// clinicaltrials.gov/ct2/show/NCT01136499. Accessed January 21, 2012.
159. Attia S,MahoneyMR, Okuno SH, et al. A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. J Clin Oncol. 2011;29(suppl):abstract 10075.
160. Mtushansky I, Coakley KE, Uldrick TS, et al. A phase I doseescalation study of azacitidine in combination with temozolamide in patients with soft tissue sarcomas. J Clin Oncol. 2011;29(suppl):abstract 10073.